Nowadays, molecular biology is key in the diagnosis and treatment of cancer, and has gone from being a field of research to an essential tool in the management of oncology patients"

Nowadays, talking about oncology means talking about "multidisciplinary teams", about advances in fields of science that are increasingly involved, and this, apart from being interesting, requires continuous specialization that is often difficult to acquire in other programs or congresses since they are oriented to a very specific area and related to a single specialty. In fact, one of the skills that TECH aims for students to achieve with this Professional master’s degree is to have a broad and clear vision of oncology and to use the comparison of scientific advances in each area as a tool that will allow them to advance in knowledge.

The Professional master’s degree in Thoracic Oncology will allow you to acquire knowledge that will be extremely useful in your daily practice based on critical work, a simple exposition and an effective methodology. For this purpose, TECH provides you with a faculty of professors who are in the first division in the management of cancer, and many leaders at an international level, who have prepared each topic in depth, from their vision and with the simplicity required to explain the subject to another specialist. Moreover, they always bear in mind that the ultimate goal of the program is that the knowledge can be acquired by any physician interested in thoracic tumors.

Finally, and with this eagerness to understand that knowledge, when it flows and nourishes all branches, allows great advances to be achieved, this program will help increase the potential of graduates thanks to the collaboration with other professionals and the revolutionary e-learning methodology.

Update your knowledge through the program in Thoracic Oncology”

This Professional master’s degree in Thoracic Oncology contains the most complete and up-to-date scientific program on the market. The most important features include:

• Development of more than 75 clinical cases presented by experts in Thoracic Oncology
• The graphic, schematic, and practical contents with which they are created provide scientific and practical information on the disciplines that are essential for professional practice
• Diagnostic-therapeutic developments in assessment, diagnosis, and intervention in Thoracic Oncology
• Practical exercises where the self-assessment process can be carried out to improve learning
• Iconography of clinical and diagnostic imaging tests
• An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the course
• Special emphasis on evidence-based medicine and research methodologies in Thoracic Oncology
• All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments
• Content that is accessible from any fixed or portable device with an Internet connection

This Professional master’s degree may be the best investment you can make when selecting a refresher program, for two reasons: in addition to updating your knowledge in Thoracic Oncology, you will obtain a qualification endorsed by TECH Global University"

The teaching staff includes professionals from the field of Thoracic Oncology, who contribute their experience to this program, as well as renowned specialists from leading scientific societies..

Thanks to its multimedia content developed with the latest educational technology, it will allow the professional a situated and contextual learning, that is to say, a simulated environment that will provide an immersive education programmed to learn in real situations.

This program is designed around Problem-Based Learning, whereby the physician must try to solve the different professional practice situations that arise throughout the program. For this purpose, the physician will be assisted by an innovative interactive video system developed by renowned experts in the field of Thoracic Oncology with extensive teaching experience.

This program offers the opportunity to learn in simulated environments, which provides an immersive learning experience designed to prepare for real-life situations"

It includes clinical cases to bring the program's content as close as possible to the reality of medical care"

The structure of the contents has been designed by a team of professionals from leading hospitals and universities, who are aware of the relevance of current education to intervene in the diagnosis and treatment of Oncological Thoracic Pathology, and who are committed to quality teaching through new educational technologies.

This Professional master’s degree in Thoracic Oncology contains the most complete and up-to-date scientific program on the market”

Module 1. Etiology, Prevention and Screening

1.1. Risk Factors and Prevention

1.1.1. Risk Factors
1.1.2. Lung Cancer and Other Respiratory Diseases (COPD, OSAHS)
1.1.3. Smoking Cessation

1.2. Solitary Pulmonary Nodule

1.2.1. Definition and Etiology. Estimation of Malignancy
1.2.2. Diagnostic Techniques in the Study of Solitary Pulmonary Nodules
1.2.3. Sequential Evaluation. Management Algorithm

1.3. Screening

1.3.1. Screening. Algorithm of Action
1.3.2. Implementation of Screening in the Healthcare System

Module 2. Translational Oncology

2.1. Molecular Biology

2.1.1. Molecular Mechanisms of Cancer
2.1.2. Tumor Immunology: Basis of Cancer Immunotherapy
2.1.3. Microenvironment Reprogramming in Lung Cancer

2.2. Translational Oncology

2.2.1. Understanding the New Technology: Next Generation Sequence (NGS) in Clinical Practice
2.2.2. Therapeutic Targets in NSCLC
2.2.3. Liquid Biopsies in NSCLC: The Future Is Here
2.2.4. Role of the Biobank in Clinical Research

Module 3. Diagnosis and Staging

3.1. Clinical Diagnosis. Serum Markers

3.1.1. Clinical Diagnosis
3.1.2. Paraneoplastic Syndromes
3.1.3. Serum Markers

3.2. Imaging Techniques

3.2.1. Chest X-ray
3.2.2. Computed Tomography (CT)
3.2.3. Thoracic Ultrasound Scan
3.2.4. Magnetic Resonance Imaging (MRI) in the Assessment of Thoracic Tumors
3.2.5. Positron Emission Tomography (PET)

3.3. Cytohistological Studies

3.3.1. Classification and Anatomopathological Study
3.3.2. Non-Invasive Methods: Sputum Cytology
3.3.3. Non-Surgical Invasive Bronchoscopic Techniques: Standard Bronchoscopy, Ultrasound (EBUS-EUS), Electromagnetic Navigation and Others
3.3.4. Transthoracic Non-Surgical Invasive Techniques: FNP, CNB, Thoracentesis and Pleural Biopsy
3.3.5. The Role of the Interventional Pathologist in the Diagnosis of Advanced Stage Lung Cancer
3.3.6. Invasive Staging in Lung Cancer

3.4. Functional and Staging Assessment

3.4.1. Preoperative Study of Surgical Risk
3.4.2. The Eighth Edition of TNM Classification of Lung Cancer

Module 4. Basis of Treatment in Thoracic Oncology

4.1. Basis and Experience of Surgical Treatment

4.1.1. Video-Assisted Thoracic Surgery. General Aspects
4.1.2. Robotic Surgery in the Treatment of Lung Cancer and Other Thoracic Tumors
4.1.3. Approach Routes to the Thorax
4.1.4. Lobectomy in the Treatment of Thoracic Tumors. Indications and Technique
4.1.5. Minor Resections in the Treatment of Thoracic Tumors
4.1.6. Pneumonectomy
4.1.7. Bronchoplastic Resections
4.1.8. Angioplastic Resections
4.1.9. Tracheal and Carinal Resection in Lung Cancer and Tracheal Tumors
4.1.10. Lymphadenectomy

4.2. Basis and Experience of Surgical Treatment

4.2.1. Evolution of Radiotherapy Treatment in Thoracic Tumors: from 3D-conformal radiotherapy to IMRT/VMAT
4.2.2. Stereotactic Radiotherapy
4.2.3. Pulmonary Brachytherapy
4.2.4. Proton Therapy for Locally Advanced Disease

4.3. Clinical trials in the Era of Personalized Oncology

4.3.1. Clinical Trials: Definitions, Examples, and Interpretation of the Literature
4.3.2. How to Design a Clinical Trial in Lung Cancer
4.3.3. Real World Data Studies: Generating Knowledge

Module 5. Localized and Locally Advanced Stage Non-Small Cell Lung Carcinoma

5.1. Early-stage NSCLC (I-II)

5.1.1. Surgical Algorithm: Technique Selection
5.1.2. Non-Surgical Algorithm: Stereotactic Radiotherapy (SRT)
5.1.3. Current Best Practice for Adjuvant Radiotherapy
5.1.4. Current Best Practice for Adjuvant Chemotherapy

5.2. NSCLC in Advanced Stage (IIIA-IIIB)

5.2.1. Management of Stage IIIA NSCLC 
5.2.2. Management of Stage IIIB NSCLC
5.2.3. Radical Radiotherapy in Stage III NSCLC
5.2.4. Concurrent and Sequential Chemotherapy Options in Stage III NSCLC
5.2.5. Toxicity of Radiochemotherapy

5.3. Tumor Pancoast

5.3.1. Diagnosis and Evaluation of Upper Lobe Tumors
5.3.2. Surgical Approach to Sulcus Tumors
5.3.3. Multidisciplinary Management of Upper Lobe Tumors

Module 6. Disseminated Stage Non-Small Cell Lung Carcinoma

6.1. NSCLC in Metastatic Stage. Targeted Therapy in the Treatment of NSCLC

6.1.1. Differentiation between the Treatment of Squamous Carcinoma and Adenocarcinoma of the Lung
6.1.2. Therapeutic Algorithm for NSCLC

6.2. Angiogenic and Targeted Therapy in the Treatment of NSCLC

6.2.1. Angiogenic Therapies in the Management of NSCLC
6.2.2. Targeted Therapy for EGFR-Positive Advanced Disease
6.2.3. Rebiopsy Recommendations After Progression to EGFR-TKIs
6.2.4. Management of EGFR-Resistant Disease
6.2.5. EML4 / ALK, ROS-1: Therapeutic Implications
6.2.6. Mechanisms of Resistance to ALK Inhibitors
6.2.7. Potential and Progress in KRAS, HER2, BRAF, PI3K, MET, TRK and RET Selection

6.3 Immunotherapy and Lung Cancer

6.3.1. PDL1: Are PDL1 Tests Interchangeable?
6.3.2. Clinical Experience and Current Recommendations for Immunotherapy
6.3.3. Immunotherapy in Patients with PD-L1-Negative NSCLC
6.3.4. Immunotherapy Beyond Immune-Control Inhibitors
6.3.5. The Role of Immunotherapy in Small Cell Lung Cancer and Other Thoracic Tumors
6.3.6. Monitoring and Management of Immune-Related Adverse Events

6.4. Oligometastatic Disease

6.4.1. Management of Oligometastatic Disease
6.4.2. Role of Surgery in Oligometastatic Disease
6.4.3. Stereotactic Radiotherapy in Extracranial Oligometastatic Disease
6.4.4. Fractionated Stereotactic Radiotherapy in Oligometastatic Brain Tumors

Module 7. Microcytic Carcinoma of the Lung and Neuroendocrine Tumors

7.1. Microcytic Carcinoma of the Lung

7.1.1. Multidisciplinary Management of Localized Disease
7.1.2. Role of Radiotherapy in Microcytic Lung Carcinoma of the Lung
7.1.3. Management of Disseminated Disease
7.1.4. Prophylactic Cranial Radiotherapy (PCR) in Microcytic Lung Carcinoma of the Lung

7.2. Neuroendocrine Tumors of the Lung

7.2.1. Molecular Biology Approach to Lung Neuroendocrine Tumors of Low and Intermediate Grade
7.2.2. Clinical Management Algorithm for Bronchial Carcinoid Tumors
7.2.3. Surgical Treatment for Pulmonary Neuroendocrine Tumors

Module 8. Tumors of the Pleura, Mediastinum and Thoracic Wall

8.1. Malignant Mesothelioma

8.1.1. Role of Surgery in Malignant Mesothelioma and Other Pleural Tumors
8.1.2. Role of Radiotherapy in Malignant Mesothelioma
8.1.3. Advanced Malignant Mesothelioma Treatment

8.2. Mediastinal Tumors

8.2.1. Prognostic and Predictive Value of the Pathologic Classification of Thymomas
8.2.2. Role of Surgery in the Treatment of Mediastinal Tumors
8.2.3. Role of Radiotherapy in Thymoma
8.2.4. Multidisciplinary Approach in Advanced Thymoma
8.2.5. New Treatments for Malignant Thymoma

8.3. Thoracic Wall Tumors

8.3.1. Clinic and Diagnosis of Primitive Thoracic Wall Tumors
8.3.2. Surgical Treatment for Primitive Thoracic Wall Tumors

8.4. Treatment of Pulmonary Metastases from Other Tumors

8.4.1. Indications for Surgical Treatment of Pulmonary Metastases from Other Tumors
8.4.2. Surgical Technique in the Treatment of Pulmonary Metastases from Other Tumors
8.4.3. Fractionated Stereotactic Radiotherapy of Pulmonary Metastases from Other Tumors

8.5. Relapses and Second Tumors

8.5.1. Detection of Relapses and Second Tumors
8.5.2. Treatment of Relapses and Second Tumors

Module 9. Collaboration in the Management of Oncology Patients

9.1. Palliative Management

9.1.1. Palliative Care: from Pre-Oncology Assessment to End-of-Life Care
9.1.2. Informed Consent: Are We Really Informing Our Patients?
9.1.3. Palliative Management of Symptoms in Lung Cancer
9.1.4. Endoscopic Palliative Treatments
9.1.5. Surgical Palliative Treatments
9.1.6. Why do Lung Cancer Cases Appear in the Emergency Department and How Can Outcomes be Improved?

9.2. Emergencies and Comorbidities

9.2.1. Palliative Radiotherapy in Brain Metastases, Spinal Cord Compression, Vena Cava Syndrome and Hemoptysis
9.2.2. Acute Management of the Patient with a Thoracic Tumor
9.2.3. Management of Respiratory Comorbidities
9.2.4. Management of Infectious Comorbidities
9.2.5. Management of Cardiovascular Comorbidities
9.2.6. Management of Neurologic Comorbidities
9.2.7. Management of Endocrinological Comorbidities
9.2.8. Management of Nutritional Comorbidities
9.2.9. Lung Cancer in the Elderly
9.2.10. Outpatient Care of Patients with Thoracic Oncological Pathology
9.2.11. Prescription of Physical Exercise in the Oncologic Patient. Prehabilitation

Module 10. From Clinical Management to Networking

10.1. Clinical Management in a Thoracic Tumor Unit

10.1.1. Basis of Clinical Management
10.1.2. Members and Functions of a Multidisciplinary Team
10.1.3. Decision-Making in a Multidisciplinary Committee

10.2. Improving Networking

10.2.1. Technological Platforms for Patient Monitoring and Control
10.2.2. The Collaborative Online World
10.2.3. Decision Support Systems in Oncology Based on Artificial Intelligence
10.2.4. Use of Big Data in Thoracic Oncology

A unique, key, and decisive learning experience to boost your professional development”